Clinical trials in Dordrecht – page 20

1 624 clinical trials in Dordrecht, The Netherlands across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in the NetherlandsKlinischOnderzoek.nl

Dordrecht at a glance

1 624

clinical trials

Research sites1

Quick filters

1 624 trials in Dordrecht

Open in trial search

Non-small cell lung cancer+1

Recruiting

A Study of MK-1084 and Drug Combination Versus Pembrolizumab and Chemotherapy for Adults with Advanced Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo

A Study of MK-1084 and Drug Combination Versus Pembrolizumab and Chemotherapy for Adults with Advanced Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Transplant rejection+1

Recruiting

A Study of Belimumab to Help Identify Safe Kidney Transplant Matches in Patients with High Antibody Levels Against Donor Tissue Types

Registered drugNo placebo

A Study of Belimumab to Help Identify Safe Kidney Transplant Matches in Patients with High Antibody Levels Against Donor Tissue Types

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Belimumab
Sponsor:Leids Universitair Medisch Centrum (LUMC)

Contact Research Centre

Beta haemolytic streptococcal infection

Recruiting

A Study of Group B Streptococcus 6-Valent Polysaccharide Conjugate Vaccine in Healthy Pregnant Women and Their Infants

Investigational

A Study of Group B Streptococcus 6-Valent Polysaccharide Conjugate Vaccine in Healthy Pregnant Women and Their Infants

Investigational

The Netherlands

Participants:0–17 years · 18–64 years · Healthy volunteers
Substances:GROUP B STREPTOCOCCUS CAPSULAR POLYSACCHARIDE IB CONJUGATED TO DIPHTHERIA TOXIN CRM197
Sponsor:Pfizer Inc.

Contact Research Centre

Breast cancer+2

Recruiting

A Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer

Registered drugNo placebo

A Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Capivasertib
Sponsor:Relay Therapeutics Inc.

Contact Research Centre

Prostate cancer

Recruiting

A study of saruparib with radiotherapy and hormone therapy for men with high-risk prostate cancer who have a BRCA gene mutation

Registered drug

A study of saruparib with radiotherapy and hormone therapy for men with high-risk prostate cancer who have a BRCA gene mutation

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Abiraterone Acetate
Sponsor:AstraZeneca AB

Contact Research Centre

Congenital cystic kidney disease

Recruiting

Testing dapagliflozin to slow kidney function decline in patients with autosomal dominant polycystic kidney disease

Registered drug

Testing dapagliflozin to slow kidney function decline in patients with autosomal dominant polycystic kidney disease

Registered drug

The Netherlands

Participants:18–64 years
Substances:Dapagliflozin
Sponsor:University Of Cologne

Contact Research Centre

Facioscapulohumeral muscular dystrophy

Recruiting

A Study Testing AOC 1020 to Improve Movement in Adults with Facioscapulohumeral Muscular Dystrophy

Investigational

A Study Testing AOC 1020 to Improve Movement in Adults with Facioscapulohumeral Muscular Dystrophy

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Sponsor:Avidity Biosciences Inc.

Contact Research Centre

Neoplasm malignant

Recruiting

A study to test the safety and effectiveness of BAY 3713372 alone and with drug combination in patients with MTAP-deleted solid tumors

Registered drugNo placebo

A study to test the safety and effectiveness of BAY 3713372 alone and with drug combination in patients with MTAP-deleted solid tumors

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:BAY 3713372
Sponsor:Bayer AG

Contact Research Centre

Bladder transitional cell carcinoma

Recruiting

A study comparing erdafitinib delivery system to chemotherapy for patients with high-risk non-muscle-invasive bladder cancer who received BCG treatment

Registered drugNo placebo

A study comparing erdafitinib delivery system to chemotherapy for patients with high-risk non-muscle-invasive bladder cancer who received BCG treatment

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Erdafitinib
Sponsor:Janssen Cilag International

Contact Research Centre

Astrocytoma malignant

Recruiting

Vorasidenib for patients with IDH-mutant grade 2 or 3 astrocytoma after completing first-line chemoradiotherapy

Investigational

Vorasidenib for patients with IDH-mutant grade 2 or 3 astrocytoma after completing first-line chemoradiotherapy

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:Vorasidenib
Sponsor:European Organisation For Research And Treatment Of Cancer

Contact Research Centre

Renal cell carcinoma

Recruiting

Testing Cabozantinib Dose Skipping Schedule Compared to Dose Reduction in Patients with Kidney Cancer Taking Cabozantinib Treatment

Registered drugNo placebo

Testing Cabozantinib Dose Skipping Schedule Compared to Dose Reduction in Patients with Kidney Cancer Taking Cabozantinib Treatment

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Cabozantinib
Sponsor:Leids Universitair Medisch Centrum (LUMC)

Contact Research Centre

Respiratory syncytial virus infection

Recruiting

Study of RSV vaccine and nirsevimab combination to prevent RSV infection in infants up to 12 months of age

Registered drugNo placebo

Study of RSV vaccine and nirsevimab combination to prevent RSV infection in infants up to 12 months of age

Registered drugNo placebo

The Netherlands

Participants:0–17 years · 18–64 years · Healthy volunteers
Substances:Nirsevimab
Sponsor:Fondazione Penta Ets

Contact Research Centre

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Dordrecht

What the registry says about research in the country

01 Hematologic Oncology

Innovative research focusing on Acute Myeloid Leukemia (AML) and various forms of Multiple Myeloma, evaluating novel drug combinations and treatment approaches for patients ineligible for intensive chemotherapy.

Blood Cancer Therapies
Leukemia Treatment
Novel Drug Combinations

Studies aim to improve survival rates and treatment outcomes in previously untreated patients.

02 Cardiovascular Medicine

Research centered on atherosclerotic cardiovascular disease and deep vein thrombosis, investigating new therapeutic approaches and preventive strategies.

Heart Disease Management
Blood Clot Prevention
Cardiac Interventions

Clinical trials focus on improving patient outcomes through innovative treatments and prevention strategies.

03 Endocrine Disorders

Studies examining treatments for thyroid conditions and hormonal disorders, comparing conventional and innovative therapeutic approaches.

Thyroid Disease Management
Hormone Therapy
Quality of Life Improvement

Research aims to enhance treatment efficacy while minimizing side effects.

Back to the Netherlands All countries